US FDA Warning Letters for inadequate Batch Records

The U.S. Food and Drug Administration (FDA) recently posted Warning Letters criticising incomplete batch production and control records.

For example, at a company in Spain, the inspector found

  • white-out correction liquid
  • unintelligible data
  • missing information such as test results and the date of approval
  • over written or crossed-out entries with "no signature, date, or explanation"
  • no proof that a second person has reviewed record "for accuracy, completeness, and compliance with established standards"

Furthermore, FDA criticised a missing identity and strength testing, an inadequate stability testing programme and - of course - "Data Integrity Remediation".

As a conclusion, FDA stated that the company's "quality systems are inadequate" and placed the firm on Import Alert.

At a site in California (USA) an investigator found that the firm was not performing final reviews of batches manufactured by a third party manufacturer before disposition. Determining the suitability of each batch for release is an essential component of your QU responsibility.

Cookies help us in providing our services. By using our services, you agree that we use cookies. Further information

OK

Go back

GMP Conferences by Topics

Cookies help us in providing our services. By using our services, you agree that we use cookies. Further information

OK